Professor David Gottlieb
Professor
Medicine, Westmead Clinical School
The Westmead Institute for Medical Research
Telephone | +61 2 9845 6033 |
Fax | +61 2 9687 2331 |
|
Biographical details
David Gottlieb trained in internal medicine and hematology at Westmead Hospital in Sydney and the Royal Free Hospital in the UK. He is currently Professor of Haematology at the University of Sydney. He has been actively involved in clinical stem cell transplantation for over 25 years and is currently a senior physician on the Westmead Hospital Blood and Marrow Transplant Unit and the Medical Director of the Sydney Cellular Therapies Laboratory. His research interests are in the field of cell and gene therapy especially in the manipulation of the immune system post-transplant to reduce opportunistic infection and recurrence of malignant disease. He is currently directing a number of clinical studies of donor-derived and third party antigen specific T cells given to rapidly reconstitute immunity in the post-stem cell transplant setting.
Selected grants
2019
- A randomized trial of cell therapy for opportunistic infection after allogeneic stem cell transplant; Gottlieb D, Blyth E; Health Administration Corporation/Research Grant.
- Development and clinical implementation of adoptive T cell therapies for haematological malignancies; Gottlieb D, Blyth E; Cancer Institute NSW/Early Career Fellowship.
- Development of a distribution pipeline for locally developed chimeric antigen receptor T-cells for adolescents and young adults with acute lymphoblastic leukaemia and lymphoma; Micklethwaite K, Gottlieb D, Blyth E; CanTeen/Clinical Trial.
2018
- Centre for Blood Transplant and Cell Therapy (CBTCT); Gottlieb D; The Leukaemia Foundation of Australia Limited/Research Grant.
- Trial of third party fungus T cells after BMT; Gottlieb D; DVC Research/Bridging Support Grant.
- The Susan and John Freeman Cancer Research Grant - First in man trial of adoptive immunotherapy using fungus-specific T cells from a cryopreserved cell bank to treat invasive fungal disease after stem cell transplant; Gottlieb D; Cancer Council New South Wales/Research Grant.
- NHMRC Centre of Research Excellence : Australia & New Zealand Musculoskeletal (ANZMUSC) Clinical Trials Network; Maher C, Buchbinder R, March L, Day R, Hinman R, Ferreira M, Harris I, Gottlieb D, Glasziou P, Green S, Billot L; National Health and Medical Research Council (NHMRC)/Centres of Research Excellence.
2017
- Centre for Blood Transplant and Cell Therapy; Hill G, Gottlieb D, Ritchie D, Curtis D, Blazar B, Ferrara J; National Health and Medical Research Council (NHMRC)/Centres of Research Excellence.
- BD FACSymphony A5 High Parameter Flow Cytometer for Westmead Research Hub at Westmead Precinct; Mann G, deFazio A, Bendall L, George J, Gottlieb D, Clarke C, Byrne J, Shaw P, Reddel R, Ling S; Cancer Institute NSW/Equipment Grant.
- Optimisation of Transposon Tools for the Clinical Production of Chimeric Antigen Receptor T-cells; Micklethwaite K, Gowrishankar K, Bendall L, Gottlieb D; Cancer Council New South Wales/Research Project Grants.
- A Phase I Study of Autologous CD19 Specific Chimeric Antigen Receptor T-cells for Therapy of Relapsed and Refractory B-cell Leukaemia and Lymphoma (The Auto-CAR19 Trial); Micklethwaite K, Gottlieb D, Dalla-Pozza L, Shaw P, O'Brien T, Trahair T; National Health and Medical Research Council (NHMRC)/Project Grants.
2016
- 3rd party T cells for previously untreated viral infection after stem cell transplant; Gottlieb D, Shaw P, Yong A, Ritchie D, Hill G; Leukemia and Lymphoma Society (USA)/Research Grant.
- A Phase I Study of PiggyBac CD19 Specific Chimeric Antigen Receptor T-cells for Therapy of Persistent and Relapsed B-cell Leukaemia and Lymphoma Post Allogeneic Stem Cell Transplantation (The CARTELL Study); Micklethwaite K, Dalla-Pozza L, Gottlieb D, O'Brien T, Trahair T, Clancy L, Blyth E, Shaw P; National Health and Medical Research Council (NHMRC)/Project Grants.
- Coadministration of malignancy and infection specific T cells after allogeneic stem cell transplant for acute leukaemia with CD34+ stem cells; Gottlieb D, Micklethwaite K, Blyth E; Cancer Council New South Wales/Research Project Grants.
- Development of a New Specific Immunosuppressive Monoclonal Antibody to Advance Transplantation; Hogarth P, Clark G, Gray P, Fazekas de St Groth B, Larsen S, Gottlieb D, Alexander S, Hennessy A, Hart D; National Health and Medical Research Council (NHMRC)/Development Grants.
2015
- Third party T cells for viral infectious in transplant patients; Gottlieb D; DVC Research/Bridging Support Grant.
2014
- Cellular therapy for HPV associated cancers and pre-cancers $115,000; Gottlieb D; DVC Research/Cancer Research Fund.
- Translating Health Discovery Project; Gottlieb D; University of Sydney/The Sydney Childrens Hospitals Network.
- A clinical trial of partially HLA-matched unrelated donor microtransplantation for prevention of relapse in patients with acute myeloid leukaemia ineligible for standard haemopoietic stem cell transplantation; Gottlieb D; National Health and Medical Research Council (NHMRC)/Project Grants.
- WAVE 20/50 Bioreactor and C5 Cell Disruptor; Chircop (nee Fabbro) M, Kizana E, Robinson P, Diefenbach R, Bryan T, Gottlieb D, Micklethwaite K, Alexander I; National Health and Medical Research Council (NHMRC)/Equipment Grants.
2013
- Clinical implications of IL7R genotype: from disease risk to disease management; Stewart G, Booth D, Gottlieb D, McKay F, Vucic S, Rajasuriar R; National Health and Medical Research Council (NHMRC)/Project Grants.
2012
- Cell therapy for the prevention and treatment of invasive filamentous fungal infections in patients with haematological malignancies; Gottlieb D, Sorrell T; National Health and Medical Research Council (NHMRC)/Project Grants.
- Establishment of a bank of third party T cells to treat virus infections (that are resistant or unsuitable for other forms of antibiotic therapy) in immunocompromised and transplant patients across Australia; Gottlieb D; National Health and Medical Research Council (NHMRC)/Project Grants.
2011
- Patient tailored immunity transplant for the prevention of viral infections post haemopoietic stem cell transplantation; Gottlieb D; National Health and Medical Research Council (NHMRC)/Project Grants.
- Autologous cellular therapy for rapid immune reconstitution in patents with CLL receiving immunisuppressive chemotherapy; Gottlieb D, Clancy L, Blyth E, Deo S; The Leukaemia Foundation of Australia Limited/Grants in Aid.
- The BD Influx High Speed Cell Sorter; Cunningham A, George J, Rizos H, Clarke C, Reddel R, Kefford R, North K, Stewart G, Jones C, Tam P, Alexander S, Gottlieb D, Bradstock K, Bryan T, Booth D, Bendall L, Brilot-Turville F, Hebbard L, Cooper S, Wang Y, Wang X; National Health and Medical Research Council (NHMRC)/Equipment Grants.
2009
- Adoptive immunotherapy for the prevention of Varicella-zoster virus reactivation post stem cell transplant; Gottlieb D, Clancy L, Clancy L; Cancer Council New South Wales/Research Project Grants.
2008
- The use of cytoxic T cells as immunotherapy for viral infections post allogenic stem cell transplant; Gottlieb D, Blyth E; The Leukaemia Foundation of Australia Limited/Postdoctoral Fellowship.
2007
- A programme of clinical adoptive immunotherapy for treatment of cytomegalovirus in stem cell transplant patients; Gottlieb D, Turtle C; Cancer Council New South Wales/Research Project Grants.
2005
- Interdisciplinary Clinical And Health Ethic Research And Training To Improve Outcomes In Immunosuppressed Haematology Patients; Sorrell T, Bradstock K, Kerridge I, Gilbert G, Gottlieb D, MacIntyre C, Dwyer D, Ankeny R; National Health and Medical Research Council (NHMRC)/Centres of Clinical Research Excellence.
- Adoptive Immunotherpay For Cmv, Vzv And Aspergillus Infection In The Immunocompromised; Gottlieb D, Sorrell T, Abendroth A; Anthony Rothe Memorial Trust/Research in NSW.
2003
- Detection and ex-vivo expansion of CMV-specific cytotoxic lymphocytes in bone marrow transplant recipients; Foster A, Gottlieb D; Cure Cancer Australia Foundation/Research Support.
- Generation of immune anti-leukemia effect using adenoviral vector gene tranfser into human myeloid leuaemia cells; Gottlieb D; DVC Research/Research and Development Scheme: Research and Development (R&D).
2002
- generation of PR-1 specific cytotoxic T lymphocytes for immunotherapy in HLA-A201+ patients with myeloid leukemia; Gottlieb D; University of Sydney/Medicine Bridging.
- Analysis of the effect of CD44 variant exon 6 expression on adhesion and migration of human leukaemic cells; Bendall L, Gottlieb D; DVC Research/Cancer Research Fund.
- generation of PR-1 specific cytotoxic T lymphocytes for immunotherapy in HLA-A201 + patients with myeloid leukaemia; Gottlieb D; DVC Research/Bridging Support Grant.
2001
- Analysis of the effect of CD44 variant exon 6 expression on adhesion and migration of human leukemic cells; Bendall L, Bradstock K, Gottlieb D; Leo and Jenny Leukaemia and Cancer Foundation/Leukaemia and Cancer Foundation.
- Generation of PR-1 specific cytotoxic T lymphocytes for immunotherapy in HLA-A201+ patients with myeloid leukaemia; Gottlieb D; University of Sydney/Cancer Research Fund.
2000
- An animal model of regulatory interactions between acute leukaemia and bone marrow stroma; Bradstock K, Gottlieb D; National Health and Medical Research Council (NHMRC)/Project Grants.
- Analysis of cellular immune response to melanoma antigens after allogenic haemopoietic stem cell transplantation; Gottlieb D, Kefford R, Bradstock K; Cancer Council New South Wales/Research Project Grants.
1999
- Expression of CD44 variants in acute myeloid leukaemia; Gottlieb D; DVC Research/Cancer Research Fund.
- Generation of allospecific T cells with anti-leukaemia specificity for HLA-identical siblings of patients with leukaemia; Gottlieb D; Anthony Rothe Memorial Trust/Research Support.
Selected publications
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|